IL6 and arthritic joint disease: For example, oral administration of LPS (1 mg) into DBA/1 mice older than 1 year old, which previously received a subarthritogenic dose (1 mg) of monoclonal antibody cocktail [66], increased the serum IL-6 levels (Figure 4(a)) and induced severe arthritis (Figure 4(b)), whereas oral administration of an LPS-adsorbent prevented the increase in serum IL-6 and development of arthritis in a dose-dependent manner.